Valinomycin as a potential antiviral agent against coronaviruses: a review
Fecha
2020Autor
Zhang, Dong
Ma, Zhi
Chen, Hanchi
Lu, Yuele
Chen, Xiaolong
Documentos PDF
Resumen
Human coronaviruses (HCoVs), including severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), have been resulting in global epidemics with heavy morbidity and mortality. Unfortunately, there are currently no specific medicines that can better treat these coronaviruses. Drug repurposing is an effective and economical strategy for drug discovery from existing drugs, natural products, and synthetic compounds. In this review, the broad-spectrum antiviral activity of valinomycin (VAL), especially its activity against coronaviruses such as SARS-CoV, MERS-CoV, human coronavirus OC43 (HCoV-OC43), were summarized, it highlights that VAL has tremendous potential for use as a novel antiviral agent against SARS-CoV-2.
Palabras clave
Coronavirus; SARS-CoV-2; Drug repurposing; Valinomycin; Antiviral agentEnlace al recurso
https://doi.org/10.1016/j.bj.2020.08.006Colecciones
Estadísticas Google Analytics
Comentarios
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.